Spyglass Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Spyglass Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84.2M	Sell	367,972 -47,577	-11%	-$10.7M	5.96%	2
2025 Q4	$88.6M	Buy	415,549 +26,902	+7%	+$5.56M	4.43%	8
2025 Q3	$77.3M	Buy	+388,647	New	+$72.5M	4.12%	14
2024 Q4	–	Sell	-652,841	Closed	-$97.5M	–	26
2024 Q3	$97.5M	Sell	652,841 -10,047	-2%	-$1.36M	6.4%	2
2024 Q2	$90.4M	Buy	662,888 +48,781	+8%	+$6.64M	6.62%	1
2024 Q1	$92.8M	Buy	614,107 +74,159	+14%	+$10.6M	6.18%	2
2023 Q4	$68M	Sell	539,948 -74,670	-12%	-$7.44M	4.89%	2
2023 Q3	$57.6M	Sell	614,618 -43,235	-7%	-$4.04M	4.51%	9
2023 Q2	$58.7M	Sell	657,853 -56,113	-8%	-$4.88M	4.24%	11
2023 Q1	$76.6M	Sell	713,966 -495	-0.1%	-$56.6K	5.77%	2
2022 Q4	$87.3M	Sell	714,461 -235,454	-25%	-$27.3M	7.01%	1
2022 Q3	$98.1M	Sell	949,915 -159,755	-14%	-$15.1M	6.94%	1
2022 Q2	$103M	Sell	1,109,670 -94,320	-8%	-$8.89M	5.73%	3
2022 Q1	$141M	Sell	1,203,990 -107,925	-8%	-$12.5M	4.83%	8
2021 Q4	$176M	Sell	1,311,915 -66,972	-5%	-$9.96M	4.68%	8
2021 Q3	$220M	Buy	1,378,887 +256,216	+23%	+$35.1M	5.04%	6
2021 Q2	$148M	Buy	1,122,671 +151,566	+16%	+$20.2M	3.29%	16
2021 Q1	$125M	Buy	971,105 +269,511	+38%	+$41M	3.3%	18
2020 Q4	$117M	Buy	701,594 +154,572	+28%	+$25.6M	3.59%	17
2020 Q3	$84.4M	Buy	547,022 +94,918	+21%	+$13.6M	3.9%	14
2020 Q2	$66.9M	Buy	452,104 +100,716	+29%	+$13.8M	4.14%	12
2020 Q1	$39.6M	Buy	351,388 +100,416	+40%	+$13M	4.47%	11
2019 Q4	$34.9M	Buy	250,972 +117,283	+88%	+$13M	4.48%	10
2019 Q3	$12.9M	Buy	133,689 +22,949	+21%	+$2.56M	3.42%	17
2019 Q2	$12.8M	Buy	110,740 +20,675	+23%	+$2.47M	4.03%	13
2019 Q1	$10.6M	Buy	90,065 +47,000	+109%	+$4.12M	4.1%	14
2018 Q4	$2.7M	Buy	+43,065	New	+$2.71M	2.02%	25

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Spyglass Capital Management's ASND Position: Q1 2026 in Review

Spyglass Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 11% in Q1 2026, selling an estimated $10.7M and leaving 367,972 shares worth $84.2M. The position accounts for 5.96% of the portfolio, ranked #2.

Spyglass Capital Management first reported a position in ASND in Q4 2018 and has held it in 27 quarters since. The position peaked at $220M in Q3 2021. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Spyglass Capital Management held 367,972 shares of Ascendis Pharma A/S worth $84.2M as of Q1 2026.
Spyglass Capital Management sold 47,577 Ascendis Pharma A/S shares in Q1 2026, an estimated $10.7M.
Ascendis Pharma A/S made up 5.96% of Spyglass Capital Management's portfolio in Q1 2026, its #2 holding.
Spyglass Capital Management first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 27 quarters since.
Spyglass Capital Management's Ascendis Pharma A/S position peaked at $220M in Q3 2021.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Spyglass Capital Management's 13F filing for Q1 2026, filed 15 May 2026.